Status of using domestical modern pharmaceutical products within health insurance coverage in public hospitals in Vietnam, 2017

Abstract

A cross - sectional descriptive study used retrospective data on the drug list in 1010 public hospitals in Vietnam with the aim of describing the current status of using domestic modern pharmaceutical products within health insurance coverage in public hospitals in Vietnam, 2017. Research results showed that Domestic drugs accounted for a higher proportion of the number of drug items (60.13%) than imported drugs and in previous years, but lower prices compared to imported drugs (32,90%); According to the procurement, the value of domestic drug money accounted for a high proportion in group 3 generics (100%) and group 4 generic (94.33%) but low in brand name drugs, and group 1 and 2 generic. According to the subgroups of pharmacological effects, there were 03 groups with the highest total drug monetary value but there were less than 50% domestic drug value: Anti-parasitic drugs, anti-infective drugs (28.67%); Cardiovascular drugs (13.17%); Drugs for cancer treatment and immunomodulatory (13.16%). From the research results above, the government should have policies to promote higher-level hospitals to increase the use of domestic drugs, as well as policies to support and promote domestic drug manufacturer production of new drug and drug groups that still accounts for a low proportion compared to imported drugs.